BioSpace News Archive

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients with Krabbe disease.

Aclarion, Inc. announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL).

AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.

Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced it has signed an agreement with a leading group ‎purchasing organization for national distribution of its cardiac monitoring solutions, Bioflux® and BiotresTM.

Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, introduces a new accessory that enables all-day scanning with any of its ten third-generation portable ultrasound scanners.

ValGenesis, Inc., the market leader in enterprise Validation Lifecycle Management Systems (VLMS), today announced that a leading pharmaceutical manufacturer selected ValGenesis VLMS to digitize multiple validation processes across the organization after a rigorous audit of possible solutions.

Shineco, Inc. announced that on January 13, 2023, the Company entered into a non-binding framework agreement with certain shareholders of Dream Partner Limited to acquire 80% equity interests of Dream Ltd., which indirectly owns 100% equity interests of Chongqing Wintus Group, which is a private company based in China that produces specialized antiviral silk fabric materials that can be widely used in the medical, hygiene, pharmaceutical and personal health fields.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”) today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD).

Pharmascience Canada is pleased to launch pms-APREMILAST, only in 30 mg tablets in Canada.

Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation, today announced that late-breaking data from the landmark EVOKE Clinical Trial was presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting.